To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
DRAVP ID DRAVPa2360
Peptide Name Sequence 14 from CN118852366A
Sequence ADSFVIRGDEVRQIAPGQ
Sequence Length 18
Source SARS-CoV-2
Target Organism SARS-CoV-2
Patent Type Patent Application
Publication Date 2024-10-29
Patent No CN118852366A
Family Info CN 118852366 A
Patent Title Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof
Comment
Abstract The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines.
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.